Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of the National Cancer Institute

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djw274PMID 28376230PMCID PMC5963793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis

  2016cited by this paper
• Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors

  2016cited by this paper
• Targeting CDK4 and CDK6: From Discovery to Therapy.

  2016cited by this paper
• Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

  2015cited by this paper
• TRKing down an old oncogene in a new era of targeted therapy.

  2015cited by this paper
• Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.

  2015cited by this paper
• BRCA1 Circos: a visualisation resource for functional analysis of missense variants

  2015cited by this paper
• Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

  2015cited by this paper
• BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

  2015cited by this paper
• Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

  2015cited by this paper
• Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

  2015cited by this paper
• CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

  2015cited by this paper
• Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

  2015cited by this paper
• Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

  2015cited by this paper
• An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

  2015cited by this paper
• The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

  2015cited by this paper
• Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment

  2015cited by this paper
• Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

  2015cited by this paper
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

  2015cited by this paper
• Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

  2015cited by this paper
• The clinical development of MEK inhibitors

  2014cited by this paper
• Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

  2014cited by this paper
• Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

  2014cited by this paper
• Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

  2014cited by this paper
• Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

  2014cited by this paper
• ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.

  2014cited by this paper
• ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

  2014cited by this paper
• NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

  2014cited by this paper
• Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

  2014influential reference
• Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).

  2014cited by this paper
• National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition

  2014influential reference
• Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.

  2014cited by this paper
• BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

  2014cited by this paper
• Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common pathogenesis

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

  2014cited by this paper
• The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

  2014cited by this paper
• The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers*

  2014cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• The Genomic Landscape of Childhood and Adolescent Melanoma

  2014cited by this paper
• FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

  2014cited by this paper
• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  2013cited by this paper
• BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

  2013influential reference
• Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

  2013cited by this paper
• Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

  2013cited by this paper
• Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

  2013cited by this paper
• Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

  2013cited by this paper
• Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

  2013influential reference
• BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

  2013influential reference
• Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949–54)

  2013cited by this paper
• Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

  2013cited by this paper
• Implementing personalized cancer genomics in clinical trials

  2013cited by this paper
• PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

  2013cited by this paper
• BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

  2013cited by this paper
• Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Designing transformative clinical trials in the cancer genome era.

  2013cited by this paper
• Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

  2013cited by this paper
• MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

  2013cited by this paper
• Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

  2013cited by this paper
• Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

  2013cited by this paper
• Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

  2013cited by this paper
• Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.

  2013cited by this paper
• Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

  2012cited by this paper
• PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

  2012cited by this paper
• Pathogenesis of NUT midline carcinoma.

  2012cited by this paper
• Targeting oncogenic BRAF in human cancer.

  2012cited by this paper
• KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

  2012cited by this paper
• Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas

  2012cited by this paper
• Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.

  2012cited by this paper
• Cyclin-dependent kinase 4/6 inhibition in cancer therapy

  2012cited by this paper
• Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

  2012cited by this paper
• MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS

  2012cited by this paper
• Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

  2011cited by this paper
• Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma

  2011cited by this paper
• PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

  2011cited by this paper
• Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

  2011cited by this paper
• Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

  2011cited by this paper
• A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies

  2011cited by this paper
• Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways

  2011cited by this paper
• Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

  2011cited by this paper
• Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

  2011cited by this paper

• Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine

  2025cites this paper
• Building Pediatric Cancer Cohorts and Accessing Data Using Childhood Cancer Data Initiative Tools.

  2025cites this paper
• Implementation of a Pediatric Oncology Precision Medicine Clinic to Personalize Approaches for Diagnosing and Treating Solid Tumors

  2025cites this paper
• NUT carcinoma of the mandible: a rare case report and literature review

  2025influential citation
• Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)

  2024cites this paper
• Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D

  2024cites this paper
• Precision oncology across the ages: Impact on children, adolescents, and young adults.

  2024cites this paper
• Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer

  2024influential citation
• Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial

  2024cites this paper
• Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

  2024cites this paper
• Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers

  2024cites this paper
• Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics

  2024cites this paper
• Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer

  2024cites this paper
• Barriers and facilitators to implementing adaptive trial designs in paediatric critical care: an international mixed-methods study

  2024cites this paper
• Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology

  2024influential citation
• The economic costs of precision medicine for clinical translational research among children with high-risk cancer

  2024cites this paper
• Clinical trial considerations for pediatric cancer drug development

  2023cites this paper
• Precision Oncology in Pediatric Cancer Surgery.

  2023cites this paper
• Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial

  2023cites this paper
• Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes

  2023cites this paper
• Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma

  2023cites this paper
• Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies

  2023cites this paper
• Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics

  2023cites this paper
• Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM

  2023cites this paper
• Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C.

  2023cites this paper
• Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma

  2023cites this paper
• Effectiveness of metronomic chemotherapy in a child with medulloblastoma: A case report

  2023cites this paper
• Precision oncology for children: A primer for paediatricians.

  2023cites this paper
• Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform

  2023cites this paper
• The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma

  2022cites this paper
• Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

  2022cites this paper
• The Role of Master Protocols in Pediatric Drug Development

  2022cites this paper
• The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors.

  2022cites this paper
• A Validation Framework for Somatic Copy Number Detection in Targeted Sequencing Panels.

  2022cites this paper
• Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial

  2022cites this paper
• Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

  2022cites this paper
• ACCELERATE - Five years accelerating cancer drug development for children and adolescents.

  2022cites this paper
• Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

  2022cites this paper
• Options of precision medicine in pediatric oncology: literature review

  2022cites this paper
• Precision medicine in pediatric solid cancers.

  2021cites this paper
• An ethics framework for consolidating and prioritizing COVID-19 clinical trials

  2021cites this paper
• Precision Medicine in Osteosarcoma: MATCH Trial and Beyond

  2021cites this paper
• Recent progress in the treatment of cancer in children

  2021cites this paper
• Case Report: Long-Term Survival of a Pediatric Patient With an Intra-Abdominal Undifferentiated Carcinoma of Unknown Primary

  2021cites this paper
• Overview and recent advances in the targeting of medulloblastoma cancer stem cells

  2021cites this paper
• Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing

  2021cites this paper
• The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

  2021cites this paper
• The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development

  2021cites this paper
• First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.

  2021cites this paper
• Modelling the Economic Impact of Next Generation Sequencing and Precision Medicine on Childhood Cancer Management—a Microsimulation Approach

  2021cites this paper
• The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?

  2021cites this paper
• Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren

  2021cites this paper
• Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma

  2020cites this paper
• Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

  2020cites this paper
• Regulatory Aspects of Genomic Medicine and Pharmacogenomics

  2020cites this paper
• Targetable BRAF and RAF1 alterations in advanced pediatric cancers.

  2020cites this paper
• Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.

  2020influential citation
• Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

  2020cites this paper
• Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices

  2020cites this paper
• Effective factors on clinical outcomes of children with osteosarcoma and Ewing bone tumors

  2020cites this paper
• The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.

  2020cites this paper
• Adaptive Phase II Trials

  2020cites this paper
• A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.

  2020cites this paper
• Basket trials: From tumour gnostic to tumour agnostic drug development.

  2020cites this paper
• Precision Medicine in Pediatric Oncology.

  2020cites this paper
• Building a better blast-trap

  2020cites this paper
• Rhabdomyosarcoma

  2019cites this paper
• Complications of biologic therapy for pediatric cancer - What the surgeon needs to know.

  2019cites this paper
• National Cancer Institute Basket/Umbrella Clinical Trials

  2019cites this paper
• Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience

  2019cites this paper
• New approaches to therapeutic drug development for childhood cancers.

  2019cites this paper
• Access to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis

  2019cites this paper
• Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors

  2019cites this paper
• Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer

  2019cites this paper
• Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours

  2019cites this paper
• Perspectives and Future Directions

  2019cites this paper
• Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria

  2019cites this paper
• Integration of a Personalized Molecular Targeted Therapy into the Multimodal Treatment of Refractory Childhood Embryonal Tumor with Multilayered Rosettes (ETMR)

  2019cites this paper
• Current and Future Strategies for Treatment of Relapsed Neuroblastoma

  2019cites this paper
• Ushering in the next generation of precision trials for pediatric cancer

  2019cites this paper
• Origins and clinical relevance of proteoforms in pediatric malignancies

  2019cites this paper
• Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols

  2019cites this paper
• Challenges and Opportunities for Childhood Cancer Drug Development

  2019cites this paper
• Precision medicine in pediatric oncology

  2018cites this paper
• Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.

  2018cites this paper
• Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies

  2018cites this paper
• Matching up

  2018cites this paper
• ALK in Neuroblastoma: Biological and Therapeutic Implications

  2018cites this paper
• Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas.

  2018cites this paper
• Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy

  2018cites this paper
• Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies.

  2018cites this paper
• Genomics of adult and pediatric solid tumors.

  2018cites this paper
• Importance of comprehensive molecular profiling for clinical outcome in children with recurrent cancer

  2018cites this paper
• Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer

  2018cites this paper
• An update on genomic-guided therapies for pediatric solid tumors.

  2017cites this paper
• Precision Medicine in Pediatric Neurooncology: A Review

  2017cites this paper
• Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours

  2017cites this paper
• Evolving paradigms for new agent development in pediatric oncology

  2017cites this paper
• Precision medicine in pediatric oncology

  2017cites this paper
• Kids Enter the MATCH.

  2017cites this paper